Isolation and characterization of a new cellular oncogene encoding a protein with multiple potential transmembrane domains

Conformational changes upon binding of a receptor loop to lipid structures: possible role in signal transduction

“…Analysis of the spectra in the presence of micelles revealed an increase in a-helical content. The fluorescence and CD data are in agreement with the predicted conformation for the whole receptor [12], where amino acids 253-266 are located in the third extracellular loop and at the beginning of transmembrane helix 7. These data suggest that the tetradecapeptide is capable of displaying a behavior similar to the one it has in the whole protein.…”

“…Here we describe studies undertaken with a tetradecapeptide :ontaining amino acids 253-266 (EYWSTFGNLHHISL) from he protein expressed by the mas oncogene [12]. This orphan 'eceptor was found to behave like a G protein-coupled receptor when stimulated by the peptide hormone angiotensin II [13].…”

Cell growth control by G protein-coupled receptors: from signal transduction to signal integration

“…Thus, it has been suggested that unrestricted activation of proliferative pathways contribute to the malignant state. Discovery of the mas oncogene (Young et al, 1986) provided the ®rst link between cellular transformation and GPCRs. The mas oncogene, which encodes a putative GPCR, was initially cloned using standard transfection assays by virtue of its ability to induce tumors in mice (Young et al, 1986).…”

“…Discovery of the mas oncogene (Young et al, 1986) provided the ®rst link between cellular transformation and GPCRs. The mas oncogene, which encodes a putative GPCR, was initially cloned using standard transfection assays by virtue of its ability to induce tumors in mice (Young et al, 1986). The natural agonist for the mas oncogene product is still unknown, but is likely to be a serum component.…”

An oncogenic fusion product of the phosphatidylinositol 3-kinase p85β subunit and HUMORF8, a putative deubiquitinating enzyme

“…However, the development of various variants of the classical focus formation assay, namely the tumorigenicity assay (Fasano et al, 1984), expression cDNA cloning (Miki et al, 1991) and expression cloning by retroviral transfer of cDNA libraries (Whitehead et al, 1995a) gradually led to the discovery of various other transforming genes including neu (Shih et al, 1981), met (Cooper et al, 1984), ret (Takahashi et al, 1985), trk (Martin-Zanca et al, 1986), raf (Shimizu et al, 1985), dbl (Eva and Aaronson, 1985), hst (Sakamoto et al, 1986), mas (Young et al, 1986), lca (Ochiya et al, 1986), B-raf (Ikawa et al, 1988), tre (Nakamura et al, 1988), vav (Katzav et al, 1989), hhc (Yang et al, 1990), ufo/axl (Janssen et al, 1991;O'Bryan et al, 1991), ect , mos (Wang et al, 1993), cot/tpl-2 (Chan et al, 1993), tim (Chan et al, 1994a), TC21 (Chan et al, 1994b), ost (Horii et al, 1994), lbc (Toksoz and Williams, 1994), FGF-8 (Lorenzi et al, 1995), lfc (Whitehead et al, 1995b), lsc (Whitehead et al, 1996) and NET1 (Chan et al, 1996).…”